Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level

Nils B. Leimkühler, Ronghui Li, MSc, Helene Gleitz, PhD, Inge Snoeren, MSc, Stijn Fuchs, Martina Crysandt, MD, Steffen Koschmieder, Christoph Kuppe, MD, Guntram Buesche, MD, Hans H Kreipe, MD PhD, Ivan Costa, PhD, Rafael Kramann, MD PhD, Rebekka K. Schneider, MD PhD

Blood (2019) 134 (Supplement_1): 1675.

https://doi.org/10.1182/blood-2019-126897

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019) 134 (Supplement_1): 4563.

https://doi.org/10.1182/blood-2019-125087

Published: 2019

Journal Articles

Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation

Sharifah Shahnaz Syed Abd Kadir, MD, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Gerald G Wulf, MD, Eva Maria Wagner, MD, Martin Bornhäuser, MD, Thomas Schroeder, MD, Martina Crysandt, MD, Karin Mayer, MD, Matthias Stelljes, Anita Badbaran, Christine Wolschke, MD, Francis A. Ayuk, MD, Ioanna N Triviai, PhD, Dominik Wolf, MD, Nicolaus Kröger, MD

Blood (2016) 128 (22): 1950.

https://doi.org/10.1182/blood.V128.22.1950.1950

Published: 2016

Journal Articles

Evidence for Premature Aging of (Clonal but also) Non-Clonal Hematopoietic Stem Cells in Patients with Acute Myeloid Leukemia (AML)

Martina Crysandt, MD, Monica S.V. Ferreira, PhD, Patrick Ziegler, PhD, Sebastian Hummel, Julian Kaufmann, Stefan Wilop, MD, Edgar Jost, MD, Wolfgang Wagner, MD PhD, Tim H. Brummendorf, MD PhD, Fabian Beier, MD

Blood (2014) 124 (21): 1048.

https://doi.org/10.1182/blood.V124.21.1048.1048

Published: 2014

Journal Articles

Sustained Alterations In Bone Marrow Stromal Cells From Patients With Myeloproliferative Neoplasms (MPN) Contribute To Remodelling Of The Bone Marrow Microenvironment Prior To The Manifestation Of Myelofibrosis

Rebekka K. Schneider, MD, Isabelle Leisten, Susanne Ziegler, PhD, Anne Schumacher, Björn Rath, MD, Dirk Fahrenkamp, Gerhard Mueller-Newen, PhD, Martina Crysandt, MD, Stefan Wilop, MD, Edgar Jost, MD, Ruth Knuechel, MD, Tim H. Bruemmendorf, MD, Patrick Ziegler, PhD

Blood (2013) 122 (21): 4102.

https://doi.org/10.1182/blood.V122.21.4102.4102

Published: 2013

Journal Articles

Response and Overall Survival Is Impaired in Obese Patients with Acute Myelogenous Leukemia

Martina Crysandt, MD, Edgar Jost, MD, Susanne Isfort, MD, Tim H Brümmendorf, Stefan Wilop, MD

Blood (2012) 120 (21): 1522.

https://doi.org/10.1182/blood.V120.21.1522.1522

Published: 2012

Journal Articles

Comparative Analysis of Hematopoiesis Supporting Capacity and Matrix Remodeling of Bone Marrow Stromal Cells Isolated From Patients with Myeloproliferative Neoplasms.

Rebekka K Schneider, MD, Isabelle Leisten, Susanne Ziegler, PhD, Anne Schumacher, Dirk Fahrenkamp, Gerhard Mueller-Newen, PhD, Martina Crysandt, MD, Edgar Jost, MD, Ruth Knuechel, MD, Tim H Brümmendorf, Patrick Ziegler, PhD

Blood (2012) 120 (21): 2864.

https://doi.org/10.1182/blood.V120.21.2864.2864

Published: 2012

Journal Articles

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

Susanne Isfort, MD, Edgar Jost, MD, Karla Bennemann, MD, Martina Crysandt, MD, Sema Akin, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 5063.

https://doi.org/10.1182/blood.V120.21.5063.5063

Published: 2012

NARROW

Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation

Evidence for Premature Aging of (Clonal but also) Non-Clonal Hematopoietic Stem Cells in Patients with Acute Myeloid Leukemia (AML)

Sustained Alterations In Bone Marrow Stromal Cells From Patients With Myeloproliferative Neoplasms (MPN) Contribute To Remodelling Of The Bone Marrow Microenvironment Prior To The Manifestation Of Myelofibrosis

Response and Overall Survival Is Impaired in Obese Patients with Acute Myelogenous Leukemia

Comparative Analysis of Hematopoiesis Supporting Capacity and Matrix Remodeling of Bone Marrow Stromal Cells Isolated From Patients with Myeloproliferative Neoplasms.

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only